EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review

Shawky E L Saaty, Hamza Salim Alshehri, Osama Alsharif, Azhar Alali, Mohamad Ibrahim Fatani iD, Abdulmajeed Alajlan iD, Shereen Hammad, Ibrahim Elnahal, Tharwat Hamad, Ali Anwar, Kamal Ahmed iD

Dermatology Research and Practice · 2026-01 · 2026 (1)

DOI: 10.1155/drp/1238540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Research and Practice, online erschienen am 15.07.2026. Verfasst von Shawky E L Saaty und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, East Jeddah Hospital, Jeddah, Saudi Arabia. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Upadacitinib is an oral, selective, and reversible Janus kinase inhibitor that has demonstrated sustained efficacy and safety over 140 weeks in clinical trials for treating atopic dermatitis (AD). We evaluated the real‐world effectiveness and impact on quality of life (QoL) of upadacitinib‐based treatment therapy in patients with moderate‐to‐severe AD in Saudi Arabia (SA).

Methods

A retrospective chart review was conducted at six sites. Data were collected from medical records of patients with AD aged ≥ 12 years who were treated with upadacitinib for a period of six months.

Results

This study included 109 AD patients, with 15.6% (17/109) being adolescents (aged 12–17) and 84.4% (92/109) being adults (aged 18 and older). The mean age was 30.9 years (57.8% males). Based on disease severity assessment by the Eczema Area and Severity Index (EASI) scoring system, severe AD was observed in 65.1% of the patients. At six months, 83.5% of the patients had an EASI score ≤ 7 and EASI‐75, EASI‐90, and EASI‐100 were achieved by 83.5%, 57.8%, and 12.8%, respectively. Dermatology life quality index (DLQI) 0/1 and pruritus Numerical Rating Scale (NRS) 0/1 at 6 months were achieved by 28.4% and 64.2%, respectively. Improvements were observed in the EASI, DLQI, and pruritus‐NRS scores from baseline to the last visit ( p < 0.001). The frequency of outpatient visits and filled prescriptions among AD patients remained stable after upadacitinib initiation, with a median (range) of 2 (1–20) outpatient visits before and 2 (1–9) after 6 months and a median (range) of 2 (1–12) filled prescriptions before compared with 2 (0–14) after 6 months. Adverse events (AEs) were reported in 10 patients, with acne being the most commonly observed.

Conclusion

Upadacitinib‐based treatment strategies showed an improvement in DLQI, EASI, and pruritus‐NRS scores in patients with moderate‐to‐severe AD in SA. No new safety signals were identified, reinforcing its favorable benefit‐risk profile in AD management.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsSaudi Arabiaatopic dermatitiseffectivenessreal worldsafetyupadacitinib

Autor:innen und Institutionen

  • Dermatology Department, East Jeddah Hospital, Jeddah, Saudi Arabia.
  • Dermatology Department, Aseer Central Hospital, Aseer, Saudi Arabia.
  • Dermatology Department, KFGH Madinah, Madinah, Saudi Arabia.
  • Dermatology Department, Hera General Hospital, Makkah, Saudi Arabia.
  • Dermatology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia, ksu.edu.sa.
  • Intercontinental Medical Affairs Department, AbbVie Biopharmaceuticals GmbH, Dubai, UAE.

ORCID-Profile: Mohamad Ibrahim Fatani, Abdulmajeed Alajlan, Kamal Ahmed

Förderung

  • AbbVie

Zitieren

APA

Saaty, S. E. L., Alshehri, H. S., Alsharif, O., Alali, A., Fatani, M. I., Alajlan, A., Hammad, S., Elnahal, I., Hamad, T., Anwar, A., & Ahmed, K. (2026). Real‐World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review. Dermatology Research and Practice, 2026(1). https://doi.org/10.1155/drp/1238540

Vancouver

Saaty SEL, Alshehri HS, Alsharif O, Alali A, Fatani MI, Alajlan A, et al. Real‐World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review. Dermatology Research and Practice. 2026;2026(1). doi:10.1155/drp/1238540

BibTeX
@article{Saaty2026,
  author = {Saaty, Shawky E L and Alshehri, Hamza Salim and Alsharif, Osama and Alali, Azhar and Fatani, Mohamad Ibrahim and Alajlan, Abdulmajeed and Hammad, Shereen and Elnahal, Ibrahim and Hamad, Tharwat and Anwar, Ali and Ahmed, Kamal},
  title = {Real‐World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review},
  journal = {Dermatology Research and Practice},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/drp/1238540}
}
Kostenlos starten →